The following topic is concerned:
The project is devoted to the development of novel vaccines of Shigella. The primary focus is to advance the development of safe, affordable, and effective vaccines for the leading causes of diarrheal and enteric diseases in low- and middle-income countries.
The industry partner should be a pharma lab accredited for production and inactivation of pathogen bacteria with the purpose of manufacturing vaccines at clinical trial level. It shall be authorised for Biosafety Level 2 (BSL2 or P2) and good manufacturing practices (GMPs) with a capacity of production in the scale of hundreds of litres.
If you are interested, please contact Marlen Damjanovic